Prostate cancer is the most frequently diagnosed cancer in men. The prostate cancer research group is concerned with the identification of biomarkers for early prostate disease, disease prognosis i.e. distinguishing inactive from potentially fatal disease, and in identifying biomarkers of response to therapy in advanced castration resistant prostate cancer.
They take a multidisciplinary approach that utilises expertise from a number of cancer researchers within and outside the precinct, as well as clinicians and pathologists, particularly colleagues at the St Vincent’s Prostate Cancer Centre and the Sydney Cancer Centre, Royal Prince Alfred Hospital. They currently aim to identify genes and pathways whose expression changes can predict the development of aggressive life-threatening prostate cancer or resistance to chemotherapy used for the treatment of advanced stage prostate cancer.
Find out more about our researchers’ research by clicking on their profiles listed on our Research Staff page.